CBER Provides List of Guidances for 2024 Post author:PacConAdmin Post published:July 8, 2024 Post category:Uncategorized Post comments:0 Comments CBER has published an updated list of guidance topics for development during 2024. Source: Drug Industry Daily Tags: aaps Read more articles Previous PostLegislative Update — Week of July 8, 2024 Next PostSun Pharma Slapped With Warning Letter for Dadra Plant’s Multiple Violations You Might Also Like Rare Cancer Drugs Carry Unique FDA Postmarketing Requirements, Say Scholars November 22, 2023 Policy Fixes Needed for “Record High” Drug Shortages, Say Researchers April 5, 2024 FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review November 7, 2024 Leave a Reply Cancel replyCommentEnter your name or username to comment Enter your email address to comment Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment.
FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review November 7, 2024